支持帕金森病患者体育活动的多组分干预措施PDConnect的可行性和可接受性:混合方法研究
Julie Jones1, Lyndsay Alexander1, Elizabeth Hancock1
1School of Health Sciences, Robert Gordon University, Aberdeen, UK.
Journal of Parkinson's disease
|March 28, 2025
概括
PDConnect在线计划是帕金森病 (PwP) 患者的可行和可接受的干预措施,促进身体活动和自我管理. 需要进一步的研究来证实它在更大的试验中的有效性.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 数字健康数字健康
背景情况:
- 身体活动对于患有帕金森病的人来说至关重要,但许多人过着久坐不动的生活.
- PDConnect是一个新的在线干预,旨在增加普华永道的PA和自我管理.
- 它整合了物理治疗,基于小组的PA,教育和行为改变策略.
研究的目的:
- 评估PDConnect干预措施的可行性和可接受性.
- 评估PDConnect对PwP体育活动,运动和非运动症状以及整体幸福感的影响.
主要方法:
- 一项混合方法研究,涉及31名PwP随机分配到PDConnect或通常护理.
- 干预包括每周物理治疗,随后是12周的小组PA和每月的支持电话.
- 可行性和可接受性是主要结果;PA,运动/非运动症状和幸福感是次要结果.
主要成果:
- 在线提供PDConnect是可行的和安全的,参与者保留率高 (74%) 和坚持.
- PDConnect参与者报告了灵活性,力量,耐力,PA信心和知识的改善.
- 在PA水平和运动功能 (UPDRS) 中发现了显著的改善,效果大小需要进一步调查.
结论:
- 对于患有帕金森病的人来说,PDConnect是一种可行的和可以接受的干预措施.
- 该计划证明了在普华永道改善体育活动和自我管理的潜力.
- 建议进行大规模试验,以确定PDConnect.的最终有效性.
相关概念视频
Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495


